newsfilter
← Latest News
Business Wire·

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Zura Bio Limited granted inducement awards of up to 250,200 Class A Ordinary Share options to five newly hired employees on October 26, 2026.
  • The awards were approved by the Compensation Committee outside the 2023 Equity Incentive Plan to comply with Nasdaq Listing Rule 5635(c)(4).
  • Each option has an exercise price of $3.56, matching the closing share price on the grant date.
  • Vesting occurs over four years, with 25% vesting after one year followed by equal quarterly installments contingent on continuous service.
  • Zura is a clinical-stage immunology company developing dual-pathway antibodies for autoimmune inflammatory diseases.
  • Lead candidate tibulizumab (ZB-106) is in Phase 2 trials for hidradenitis suppurativa systemic sclerosis, with a third study for polymyalgia rheumatica planned before year-end 2026.
  • Candidates torudokimab (ZB-880) crebankitug (ZB-168) completed Phase 1/1b studies are now being evaluated for various autoimmune conditions.